MedTrace Logo

A Study to Assess the Safety of HIV and Hep C Vaccine Candidates When Given Separately or in Combination

NCT02362217 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2018-10-11

No results posted yet for this study

Summary

This study is aimed at assessing the safety of candidate Hepatitis C vaccines AdCh3NSmut/MVA-NSmut and HIV vaccines ChAdV63.HIVconsv/MVA.HIVconsv when administered separately or in combination to healthy volunteers. The study also aims to assess the cellular immune response generated by these vaccines when administered as mentioned above.

Conditions

  • Hepatitis C Infection
  • HIV Infection

Interventions

BIOLOGICAL

AdCh3NSmut1

Genetic vaccine against Hepatitis C virus infection

BIOLOGICAL

MVA-NSmut

Genetic vaccine against Hepatitis C virus infection

BIOLOGICAL

ChAdV63.HIVconsv

Genetic vaccine against HIV-1 infection

BIOLOGICAL

MVA.HIVconsv

Genetic vaccine against HIV-1 infection

Sponsors & Collaborators

  • ReiThera Srl

    collaborator INDUSTRY

  • GlaxoSmithKline

    collaborator INDUSTRY

  • University of Oxford

    lead OTHER

Principal Investigators

  • Lucy Dorrell, Prof. · University of Oxford

  • Ellie Barnes, Prof. · University of Oxford

  • Tomas Hanke, Prof. · University of Oxford

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2016-08-31
Completion
2017-10-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02362217 on ClinicalTrials.gov